About AMP
The goal of the Accelerating Medicines Partnership (AMP) is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment.
Overview
The goal of the Accelerating Medicines Partnership (AMP) is to bring together the resources of NIH and industry to improve our understanding of disease pathways and facilitate better selection of targets for treatment. (Read the program description by NIH here.) Collaborations with 10 companies and three NIH Institutes have been established across five major disease areas: Alzheimer's disease, Type 2 diabetes, Rheumatoid Arthritis (RA)/Lupus, Parkinson's disease and Schizophrenia.
Partners
Private-Sector Partners:
-
AbbVie*
-
Biogen*
-
Bristol-Myers Squibb Company*
-
Eli Lilly and Company*
-
GlaxoSmithKline*
-
Johnson & Johnson*
-
Merck & Co., Inc.*
-
Pfizer Inc*
-
Pharmaceutical Research and Manufacturers of America*
-
Sanofi*
- Takeda Pharmaceuticals International, Inc.*
*Provided financial or in-kind support for this program.
Click below to view partners of the other AMP collaborations:
FNIH Contact
- David Wholley, M.Phil., Senior Vice President of Research Partnerships, dwholley@fnih.org